DinutuximabNKTR-255
… a dose of 0.5-1x10e7 cells/animal once every week for 5 weeks. Dinutuximab was administered via IP injection at 15 ug/animal twice a week.…
5articles mentioning drugs
36drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: NKTR-255 ×
NKTR-255
This drug is selected. Its supporting articles are shown below.
Articles mentioning NKTR-255
5 articles · page 1 of 190.9%
NKTR-255Acute myeloid leukemianeuroblastomaAML
…ther enhance anti-AML efficacy of CD33.CAR NK cells and whether NKTR-255 (polymer conjugated IL15)3 further augments these effects.Metho…
Ciurea SOcam161533NKTR-255neuroblastomaAMLacute myelogenous leukemia
…ly relapsed and refractory AML. Am J Hematol 2024:99(5):890-899.Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, C…
NKTR-255HSV C021neuroblastomaGlioblastomaGBM
…expressing human IL-21(HSV C021) in combination with ROR1.CAR.5 NKTR-255 is an investigational IL-15Rα-dependent, polymer-conjugated IL-…
dinutuximabNKTR-255IL-15 agonistEwing sarcomaES
…dependent cellular cytotoxicity (ADCC) via an anti-GD2 antibody dinutuximab, and improving NK cell persistence and ADCC by an IL-15 agonist…